Successful medical treatment with danazol after failed embolization of uterine arteriovenous malformation

Case report OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

A 29-year-old woman with a uterine arteriovenous malformation achieved lesion resolution with danazol after failed embolization, remaining symptom-free for 16 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Transcatheter arterial embolization has been the therapy of choice for uterine arteriovenous malformations, whereas medical therapy has not been popular because of patient propensity to bleed. CASE: A 29-year-old woman, gravida 3, para 0, was diagnosed with uterine arteriovenous malformation. Because initial treatment with uterine artery embolization was unsuccessful, she was ultimately treated with danazol. Resolution of the lesion after 2 weeks of danazol therapy was observed. As of follow-up at 16 months, she has remained free from further abnormal bleeding episodes and recurrence of the lesion. CONCLUSION: Danazol has the potential for medical management of uterine arteriovenous malformations in hemodynamically stable patients who do not respond to embolization.

My notes (saved in your browser only)

MeSH descriptors

Arteriovenous Malformations Danazol Estrogen Antagonists Adult Arteriovenous Malformations Arteriovenous Malformations Arteriovenous Malformations Danazol Embolization, Therapeutic Estrogen Antagonists Female Humans Treatment Failure Ultrasonography Uterine Hemorrhage Uterine Hemorrhage Uterine Hemorrhage Uterine Hemorrhage Uterus Uterus

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (3)

References (6)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-11T06:01:13.017405+00:00
pubmed
last seen: 2026-10-08T21:02:06.159351+00:00
unpaywall
last seen: 2026-10-27T06:37:41.825712+00:00
License: CC0 · commercial use OK